Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumor invasion and angiogenesis

Cancer Letters

Volumn 271, Issue 1, 2008, Pages 105-116

  Xie, Yufeng ^a   Zhang, Haifeng ^a   Sheng, Weihua ^a   Xiang, Jim ^b   Ye, Zhenmin ^b   Yang, Jicheng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adenoviral vector; Humanized; ING4; Lung carcinoma; Vector modification

Indexed keywords

ADENOVIRUS VECTOR; ALANINE; ARGININE; GELATINASE A; GELATINASE B; GENE PRODUCT; INTERLEUKIN 6; INTERLEUKIN 8; LYSINE; PROTEIN ING4; THREONINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ING4 GENE; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HOMEODOMAIN PROTEINS; LUNG NEOPLASMS; MICE; MUTAGENESIS, SITE-DIRECTED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

ADENOVIRIDAE; MURINAE; MUS;

EID: 53049089584     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.05.050     Document Type: Article

References (45)

1. Garkavtsev I., Kazarov A., Gudkov A., and Riabowol K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat. Genet. 14 (1996) 415-420
2. Saito A., Furukawa T., Fukushige S., Koyama S., Hoshi M., Hayashi Y., and Horii A. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p33/ING1. J. Hum. Genet. 45 (2000) 177-181
3. Garkavtsev I., Grigorian I.A., Ossovskaya V.S., Chernov M.V., Chumakov P.M., and Gudkov A.V. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391 (1998) 295-298
4. Helbing C.C., Veillette C., Riabowol K., Johnston R.N., and Garkavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res. 57 (1997) 1255-1258
5. Nagashima M., Shiseki M., Miura K., Hagiwara K., Linke S.P., Pedeux R., Wang X.W., Yokota J., Riabowol K., and Harris C.C. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA 98 (2001) 9671-9676
6. Nagashima M., Shiseki M., Pedeux R.M., Okamura S., Kitahama-Shiseki M., Miura K., Yokota J., and Harris C.C. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 22 (2003) 343-350
7. Gunduz M., Ouchida M., Fukushima K., Ito S., Jitsumori Y., Nakashima T., Nagai N., Nishizaki K., and Shimizu K. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. Oncogene 21 (2002) 4462-4470
8. He G.H., Helbing C.C., Wagner M.J., Sensen C.W., and Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol. Biol. Evol. 22 (2005) 104-116
9. Aasland R., Gibson T.J., and Stewart A.F. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem. Sci. 20 (1995) 56-59
10. Zhang X., Wang K.S., Wang Z.Q., Xu L.S., Wang Q.W., Chen F., Wei D.Z., and Han Z.G. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem. Biophys. Res. Commun. 331 (2005) 1032-1038
11. Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K., Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J., and Harris C.C. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 63 (2003) 2373-2378
12. Zhang X., Xu L.S., Wang Z.Q., Wang K.S., Li N., Cheng Z.H., Huang S.Z., Wei D.Z., and Han Z.G. ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett. 570 (2004) 7-12
13. Garkavtsev I., Kozin S.V., Chernova O., Xu L., Winkler F., Brown E., Barnett G.H., and Jain R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428 (2004) 328-332
14. Kim S., Chin K., Gray J.W., and Bishop J.M. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc. Natl. Acad. Sci. USA 101 (2004) 16251-16256
15. Ozer A., Wu L.C., and Bruick R.K. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc. Natl. Acad. Sci. USA 102 (2005) 7481-7486
16. Unoki M., Shen J.C., Zheng Z.M., and Harris C.C. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J. Biol. Chem. 281 (2006) 34677-34686
17. Gunduz M., Nagatsuka H., Demircan K., Gunduz E., Cengiz B., Ouchida M., Tsujigiwa H., Yamachika E., Fukushima K., Beder L., Hirohata S., Ninomiya Y., Nishizaki K., Shimizu K., and Nagai N. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 356 (2005) 109-117
18. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer statistics, 2001. CA Cancer J. Clin. 51 (2001) 15-36
19. Naruke T., Goya T., Tsuchiya R., and Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J. Thorac. Cardiovasc. Surg. 96 (1988) 440-447
20. Wu Q., Xia D., Carlsen S., and Xiang J. Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Curr. Gene Ther. 5 (2005) 237-247
21. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95 (1998) 2509-2514
22. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
23. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat. 36 (1995) 169-180
24. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
25. Bates S., Ryan K.M., Phillips A.C., and Vousden K.H. Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. Oncogene 17 (1998) 1691-1703
26. Medema R.H., Klompmaker R., Smits V.A., and Rijksen G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 16 (1998) 431-441
27. Niculescu A.B., Chen X., Smeets M., Hengst L., Prives C., and Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18 (1998) 629-643
28. Smits V.A., Klompmaker R., Vallenius T., Rijksen G., Makela T.P., and Medema R.H. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J. Biol. Chem. 275 (2000) 30638-30643
29. Colla S., Tagliaferri S., Morandi F., Lunghi P., Donofrio G., Martorana D., Mancini C., Lazzaretti M., Mazzera L., Ravanetti L., Bonomini S., Ferrari L., Miranda C., Ladetto M., Neri T.M., Neri A., Greco A., Mangoni M., Bonati A., Rizzoli V., and Giuliani N. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 {alpha} (HIF-1{alpha}) activity: involvement in myeloma-induced angiogenesis. Blood 110 (2007) 4464-4475
30. Motro B., Itin A., Sachs L., and Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc. Natl. Acad. Sci. USA 87 (1990) 3092-3096
31. Lin Y., Huang R., Chen L., Li S., Shi Q., Jordan C., and Huang R.P. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int. J. Cancer 109 (2004) 507-515
32. Strieter R.M., Kunkel S.L., Elner V.M., Martonyi C.L., Koch A.E., Polverini P.J., and Elner S.G. Interleukin-8. A corneal factor that induces neovascularization. Am. J. Pathol. 141 (1992) 1279-1284
33. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
34. Liotta L.A. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 46 (1986) 1-7
35. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516
36. Shen J.C., Unoki M., Ythier D., Duperray A., Varticovski L., Kumamoto K., Pedeux R., and Harris C.C. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 67 (2007) 2552-2558
37. Aimes R.T., and Quigley J.P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J. Biol. Chem. 270 (1995) 5872-5876
38. Jr Kleiner D.E., and Stetler-Stevenson W.G. Structural biochemistry and activation of matrix metalloproteases. Curr. Opin. Cell Biol. 5 (1993) 891-897
39. Cottam D.W., Rennie I.G., Woods K., Parsons M.A., Bunning R.A., and Rees R.C. Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Invest. Ophthalmol. Vis. Sci. 33 (1992) 1923-1927
40. Jiang M.C., Liao C.F., and Lee P.H. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem. Biophys. Res. Commun. 282 (2001) 671-677
41. Vincenti M.P., Coon C.I., and Brinckerhoff C.E. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum. 41 (1998) 1987-1994
42. Han Y.P., Tuan T.L., Wu H., Hughes M., and Garner W.L. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J. Cell Sci. 114 (2001) 131-139
43. Eberhardt W., Huwiler A., Beck K.F., Walpen S., and Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J. Immunol. 165 (2000) 5788-5797
44. Sato H., and Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8 (1993) 395-405
45. Doyon Y., Cayrou C., Ullah M., Landry A.J., Cote V., Selleck W., Lane W.S., Tan S., Yang X.J., and Cote J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 21 (2006) 51-64